Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFenner PLC Regulatory News (FENR)

  • There is currently no data for FENR

AGM Trading Update

14 Jan 2015 07:00

RNS Number : 0822C
Fenner PLC
14 January 2015
 



14 January 2015

 

Fenner PLC

("Fenner" or "the Group")

 

AGM Trading Update

 

Overview

Trading in the period since 11th November 2014 has been characterised by a good performance by the AEP Division and an increasingly challenging environment in the ECS Division. In response to these conditions and the anticipated impact of the fall in oil prices on demand for oil and gas products within AEP, we have further increased our focus on margin control across the Group. Whilst seeking to ensure that the Group preserves its flexibility to respond to any recovery in its markets, cost reduction programmes have been implemented or accelerated and selected capital projects have been deferred across the Group.

AEP

Trading in the AEP division overall has been in line with expectations during the period, continuing the trend of improving performance reported in the second half of last year. The recent, precipitous fall in oil prices is expected to affect demand levels in those AEP businesses directly involved in the oil and gas industry from early in calendar year 2015. The non-oil, speciality polymer businesses in AEP, which represent approximately two-thirds of divisional turnover, are expected to continue to perform in line with expectations. Notwithstanding satisfactory current activity levels in the oil and gas related businesses, cost bases are being reduced in advance of the expected reduction in demand levels arising from oil prices, which are now widely expected to remain at or around current levels. These pre-emptive cost reductions are being carefully targeted to ensure that we retain our ability to continue to develop the business effectively.

ECS

Against a continuing backdrop of global mineral oversupply and correspondingly low commodity prices, any recovery in our ECS markets continues to be deferred. Demand levels in the Americas are stable, albeit at low levels, anticipated growth in EMEA has not been achieved and margins continue to decline in Australia as a result of customer-driven price pressures. In response to these circumstances, additional cost reductions are now being implemented in all territories to further protect trading margins. With only minimal near-term capital investment required in our ECS facilities, which have been well-invested through the programmes of the past decade, cash conversion is expected to be strong.

Outlook

Our balance sheet is strong, with borrowings remaining in line with expectations. We will complete the major project to consolidate our medical manufacturing facilities in the USA, which is vital to allow continuing strategic growth. Other capital programmes for 2015 are being curtailed to include only essential or near-term payback projects. In addition, future major projects have been deferred pending improved market conditions, which is currently expected to result in significantly lower capital expenditure in 2016 than previously indicated.

In addition to ongoing programmes to aggressively manage variable costs, these new management actions will reduce the run rate of cash overhead expenditure across the group by an incremental £9m on an annualised basis.

Recognising the anticipated effect of lower oil prices and the challenging trading conditions in ECS, offset by cost reductions across the Group, we now anticipate 2015 full year earnings to be slightly below our previous range of expectations. In addition, an exceptional charge will arise from implementation of the cost savings initiated during this year. Our actions leave the group well positioned to take advantage of recovery when it occurs.

 

Analyst and Investor conference call

A conference call for analysts and investors will be held at 8:30 a.m. (UK time) today to discuss this statement. Participants can join the call on + 44 (0)20 3059 8125. A recording of this conference call will be available for 7 days on + 44 (0)121 260 4861 using the access code 0090801 followed by #.

Forward-looking statements

Certain statements contained in this statement constitute forward-looking statements. Such forward-looking statements involve risks, uncertainties and other factors which may cause the actual results, performance or achievements of Fenner, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such statements.

 

For further information please contact:

Fenner PLC

Nicholas Hobson, Chief Executive OfficerRichard Perry, Group Finance Director

today: 020 7067 0700thereafter: 01482 626501

Weber Shandwick Financial

Nick Oborne / Tom Jenkins

020 7067 0700

 

Notes to editors:

Fenner PLC is a world leader in reinforced polymer technology, providing local engineered solutions for performance-critical applications. The Group operates through two divisions:

Engineered Conveyor Solutions: the ECS division, trading under the Fenner Dunlop, Fenner and Dunlop brand names, is a recognised leader in the global conveying market. The division offers a unique, comprehensive suite of products and services, which serve the conveying needs of mining, power generation and bulk handling markets.

Advanced Engineered Products: the AEP division uses advanced polymeric materials and technical expertise to provide high value-added solutions to customers' most challenging engineering problems. Customers are spread across a variety of end-user segments, including oil & gas and medical which account for some 40 per cent of divisional revenue, together with construction, transportation, automation and general industrial. AEP's trading names are recognised globally and include CDI Energy Products, EGC Critical Components, Hallite, AIP Precision Machining, Fenner Precision, Fenner Drives, James Dawson, Mandals, Secant Medical and Xeridiem.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTGGUQUGUPAGBW
Date   Source Headline
28th Oct 20154:16 pmRNSHolding(s) in Company
22nd Oct 20159:41 amRNSHolding(s) in Company
19th Oct 20152:36 pmRNSHolding(s) in Company
7th Oct 20159:20 amRNSHolding(s) in Company
10th Sep 20153:34 pmRNSHolding(s) in Company
10th Sep 201511:49 amRNSHolding(s) in Company - Amendment
9th Sep 20154:02 pmRNSHolding(s) in Company
9th Sep 20151:24 pmRNSHolding(s) in Company
8th Sep 20157:00 amRNSPre-Close Trading Statement
4th Sep 20153:06 pmRNSHolding(s) in Company
2nd Sep 20151:13 pmRNSHolding(s) in Company
2nd Sep 20159:34 amRNSBlocklisting Interim Review
24th Jul 201511:11 amRNSHolding(s) in Company
22nd Jul 20157:00 amRNSTrading Update
6th Jul 201510:16 amRNSHolding(s) in Company
17th Jun 20154:39 pmRNSHolding(s) in Company
28th Apr 201511:09 amRNSHolding(s) in Company
22nd Apr 20157:00 amRNSHalf Yearly Report
20th Apr 20153:53 pmRNSHolding(s) in Company
10th Apr 20152:21 pmRNSHolding(s) in Company
8th Apr 20152:37 pmRNSHolding(s) in Company
2nd Apr 20159:37 amRNSHolding(s) in Company
25th Mar 20154:07 pmRNSHolding(s) in Company
20th Mar 20158:46 amRNSHolding(s) in Company
19th Mar 20151:31 pmRNSHolding(s) in Company
12th Mar 20157:00 amRNSPre-Close Trading Statement
2nd Mar 201511:23 amRNSBlocklisting Interim Review
2nd Feb 20157:00 amRNSAcquisition
30th Jan 20153:54 pmRNSDirector/PDMR Shareholding
29th Jan 20151:24 pmRNSDirector/PDMR Shareholding
21st Jan 201511:10 amRNSDirectorate Change
21st Jan 201511:08 amRNSDirector Declaration
15th Jan 201512:09 pmRNSResult of AGM
14th Jan 20157:00 amRNSAGM Trading Update
1st Dec 201411:44 amRNSDirector/PDMR Shareholding
21st Nov 20141:03 pmRNSDirector/PDMR Shareholding
21st Nov 201411:36 amRNSDirector/PDMR Shareholding
21st Nov 201411:27 amRNSDirector/PDMR Shareholding
20th Nov 20143:34 pmRNSDirector/PDMR Shareholding
18th Nov 201410:46 amRNSDirector/PDMR Shareholding
12th Nov 201410:01 amRNSDirector/PDMR Shareholding
11th Nov 20147:00 amRNSFinal Results
6th Nov 201410:03 amRNSHolding(s) in Company
5th Nov 20142:38 pmRNSHolding(s) in Company
23rd Sep 20149:26 amRNSHolding(s) in Company
9th Sep 20147:00 amRNSPre-Close Trading Statement
2nd Sep 20144:04 pmRNSTotal Voting Rights
2nd Sep 20142:57 pmRNSDirector/PDMR Shareholding
2nd Sep 20142:44 pmRNSBlocklisting Interim Review
27th Aug 20149:38 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.